Reassessing the need for primary prevention implantable cardioverter-defibrillators in contemporary patients with...

Area of Science:

• Cardiology
• Electrophysiology
• Medical Devices

Background:

• Implantable cardioverter-defibrillators (ICDs) are crucial for preventing sudden cardiac death (SCD) from ventricular tachyarrhythmia (VTA).
• Current guidelines recommend prophylactic ICDs for primary prevention of SCD in heart failure with reduced ejection fraction (HFrEF) patients without prior sustained VTA.
• These recommendations stem from trials over 20 years old and may not reflect current HFrEF patient profiles, who exhibit lower arrhythmic risk due to advanced medical therapies.

Purpose of the Study:

• To review the clinical equipoise surrounding routine primary prevention ICD implantation in contemporary HFrEF patients.
• To examine the rationale for new clinical trials reassessing the role of ICDs in this population.
• To address the unmet need for improved patient selection for primary prevention ICDs.

Main Methods:

• Review of existing clinical trial data and guidelines.
• Analysis of contemporary HFrEF patient characteristics and risk factors.
• Discussion of the evolving landscape of heart failure management.

Main Results:

• Clinical equipoise exists regarding the necessity of routine primary prevention ICDs in current HFrEF populations.
• Advances in heart failure medical therapies have potentially reduced the arrhythmic risk in HFrEF patients.
• Existing guidelines may overestimate the benefit of ICDs for primary prevention in contemporary HFrEF patients.

Conclusions:

• There is a need to re-evaluate the role of primary prevention ICDs in HFrEF.
• Contemporary HFrEF patients may require different selection criteria for ICD implantation.
• Future clinical trials are essential to guide evidence-based decision-making for ICD use in HFrEF.